【摘要】 目的探讨莫西沙星与左氧氟沙星辅助治疗AECOPD临床疗效及安全性差异。方法选取AECOPD患者160例,随机分为A组(80例)和B组(80例),分别采用左氧氟沙星和莫西沙星辅助治疗,比较两组患者临床疗效和安全性。结果 B组患者临床疗效和细菌清除率显著优于A组(P<0.05);B组患者1年内再次急性发作次数显著低于A组(P<0.05);B组患者临床症状体征改善时间和治疗后7 d、10 d肺部X线摄片好转率均显著优于A组(P<0.05);B组患者毒副作用发生率显著低于A组(P<0.05)。结论莫西沙星辅助治疗AECOPD在临床疗效及安全性方面均优于左氧氟沙星。更多还原

【Abstract】 Objective To investigate the clinical effect and safety difference between moxifloxacin and levofloxacin in adjunctive treatment of AECOPD. Methods 160 patients with AECOPD were chosen and randomly divided into the group A( 80 patients) with levofloxacin adjunctive treatment and the group B( 80 patients) with moxifloxacin adjunctive treatment. Their clinical efficacy and safety were compared between the two groups. Results The clinical efficacy and clearance rate of pathogenic bacteria were significantly better in the group B than in the group A( P < 0. 05). The improved time of clinical signs and symptoms and the improvement rate of pulmonary radiograph 7and 10 days after treatment were significantly better in the group B than in the group A( P < 0. 05). The number of acute exacerbation in 1 year was significantly lower in the group B than in the group A( P < 0. 05). The incidence of toxic and side effect was significantly lower in the group B than in the group A( P < 0. 05). Conclusion Compared with levofloxacin,moxifloxacin has better efficacy and safety in adjunctive treatment of AECOPD.更多还原